Universidad Internacional del Ecuador
Universidad Internacional del Ecuador Quito: Repositorio Digital UIDENot a member yet
4856 research outputs found
Sort by
Leucine-rich α-2-glycoprotein 1 can be a novel angiogenic mediator in autosomal dominant polycystic kidney disease
No full textObjectives In the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD), hypoxia-associated angiogenesis is increasingly considered a significant mechanism. We aimed to assess serum and urine leucine-rich alpha-2-glycoprotein 1 (LRG1) levels and their correlation with vascular endothelial growth factor A (VEGF-A), hypoxia-inducible factor 1-alpha (HIF-1 alpha), and disease severity to explore LRG1's role as a biochemical marker in ADPKD-related angiogenesis. Methods The study involved 67 ADPKD patients and 25 healthy controls. The ADPKD-I group comprised 40 patients with an estimated glomerular filtration rate (eGFR, mL/min/1.73 m2) >60, and the ADPKD-II group comprised 27 patients with an eGFR <60. Height-adjusted total kidney volume (hTKV) was calculated from magnetic resonance (MR) images. Serum levels of LRG1, VEGF-A, HIF-1 alpha, and urine LRG1 levels were assayed by ELISA, and urinary albumin levels were measured by the immunoturbidimetric method. Urine LRG and albumin levels were calculated by normalizing the urine creatinine ratio. Results The levels of serum LRG1 were remarkably higher only in the ADPKD-II group compared to controls (p<0.025). Serum HIF-1 alpha and VEGF-A levels were significantly elevated in both ADPKD-I and ADPKD-II groups compared to controls (p = 0.039, p = 0.029, p<0.001, and p<0.001, respectively); however, there was no notable difference between two groups. Urinary LRG1 and albumin excretion levels were notably higher in both ADPKD groups than in controls but the highest in the ADPKD-II group. In the ADPKD-I group, urine LRG1 correlated positively with urinary albumin excretion (r = 0.338, p = 0.038). Conclusions LRG1 may serve as a mediator in the crosstalk between hypoxia and angiogenesis in patients with ADPKD. Additionally, urinary LRG1 levels could potentially reflect disease severity
Yirmi Dört Saatlik Ambulatuar Kan Basıncı Monitörizasyonu İle Yeni Tanı Konan Hipertansiyon Hastalarında Optik Disk Ve Retinal Mikrovaskülaritenin Değerlendirilmesi
No full textCulinary Culture and Local Food Practices in Post-Earthquake Temporary Living Spaces: A Qualitative Evaluation in Hatay
No full text
Krizde sessiz direnç yayılımı: Deprem sonrası izole edilen gram negatif üriner patojenlerde antibiyotik direnci ve direnç genlerinin moleküler epidemiyolojisi
No full text
Theoretical Investigations on Vic-Dioxime Complexes Coordinated with Cu(II) and Ni(II) Ions: Using Density Functional Theory
No full textHATAY İLİNDE GELENEKSEL KAFES VE SERBEST SİSTEMDE YUMURTA ÜRETİCİLİĞİ YAPAN İŞLETMELERİN SORUNLARI VE ÇÖZÜM ÖNERİLERİ
No full textPharmacokinetics and Plasma Protein Binding of Flunixin in Rainbow Trout (<i>Oncorhynchus mykiss</i>)
No full textFlunixin's pharmacokinetics, bioavailability, and plasma protein binding were examined in rainbow trout. The experiment involved 252 rainbow trout (Oncorhynchus mykiss) maintained at 12 +/- 0.6 degrees C. Flunixin was administered to rainbow trout via intravascular (IV), intramuscular (IM), and oral routes at a dosage of 2.2 mg/kg. Plasma samples were collected at times 0 (control), 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 48, 72, and 96 h. High-pressure liquid chromatography-ultraviolet was employed to quantify flunixin concentrations. The elimination half-life (t(1/2 lambda z)) for flunixin was 8.37 h for IV, 8.68 h for IM, and 8.76 h for oral. The t(1/2 lambda z) was similar between administration groups. The volume of distribution at a steady state and total body clearance were 55.81 mL/kg and 6.83 mL/h/kg, respectively, after IV administration. The mean peak plasma concentration was 6.24 +/- 0.41 mu g/mL at 4 h for oral administration and 13.98 +/- 0.86 mu g/mL at 2 h for IM administration. The in vitro protein binding ratio of flunixin in rainbow trout plasma was 96.34 +/- 2.29%. The bioavailability of flunixin after oral (25.74%) administration was lower than that after IM (66.70%) administration. Thus, developing an oral pharmaceutical formulation that can be administered with feed and has high bioavailability could enhance the therapeutic effect